Comparative effects of 28-day treatment with the new anti-estrogen em- 800 and tamoxifen on estrogen-sensitive parameters in intact mice

International Journal of Cancer

Volumn 73, Issue 3, 1997, Pages 381-391

  Luo, Shouqi ^a   Martel, Céline ^a   Sourla, Antigone ^a   Gauthier, Sylvain ^a   Mérand, Yves ^a   Belanger, Alain ^a   Labrie, Claude ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANTIESTROGEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CELL; ENZYME ACTIVITY; ESTROGEN SYNTHESIS; GROWTH INHIBITION; HORMONE RESPONSE; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RECEPTOR AFFINITY; VAGINA EPITHELIUM;

17-HYDROXYSTEROID DEHYDROGENASES; ANDROSTENEDIONE; ANIMALS; ATROPHY; BENZOPYRANS; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIUM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTRONE; FEMALE; MICE; MICE, INBRED BALB C; ORGAN SIZE; OVARIECTOMY; PROPIONATES; RECEPTORS, ESTROGEN; TAMOXIFEN; TESTOSTERONE; UTERUS; VAGINA;

EID: 0030723512     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971104)73:3<381::AID-IJC13>3.0.CO;2-G     Document Type: Article

References (28)

1. ASSELIN, J., KELLY, P.A., CARON, M.G. and LABRIE, F., Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology, 101, 666-671 (1977).
2. ASSELIN, J. and LABRIE, F., Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J. Steroid Biochem., 9, 1079-1082 (1978).
3. BRADFORD, MM., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976).
4. BUCOURT, R., VIGNAU, M. and TORELLI, V., New biospecific absorbents for the purification of estradiol receptor. J. biol. Chem., 253, 8221-8228 (1978).
5. DAUVOIS, S., GENG, C.S., LÉVESQUE, C., MÉRAND, Y. and LABRIE, F., Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res., 51, 3131-3135 (1991).
6. DE LAUNOIT, Y., DAUVOIS, S., DUFOUR, M., SIMARD, J. and LABRIE, F., Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-(16′α-chloro-3′,17β-dihydroxy- estra- 1′,3′,5′-(10′)triene-7′α-yl)undecanamide in human breast cancer ZR-75-1 cells. Cancer Res., 51, 2797-2802 (1991).
7. DROUIN, J., LAGACÉ, L. and LABRIE, F., Estradiol-induced increase of the LH responsiveness to LHRH in rat anterior pituitary cells in culture. Endocrinology, 99, 1477-1481 (1976).
8. DUKES, M., MILLER, D., WAKELING, A.E. and WATERTON, J.C., Antiuterotrophic effects of a pure antioestrogen. ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J. Endocrinol., 135, 239-247 (1992).
9. FERLAND, L., DROUIN, J. and LABRIE, F., Role of sex steroids on LH and FSH secretion in the rat. In: F. Labrie, J. Meites and G. Pelletier (eds.), Hypothalamus and endocrine functions, pp. 191-209, Plenum Press, New York (1976).
10. FORNANDER, T., HELLSTRÖM, A.C. and MOBERGER, B., Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J. nat. Cancer Inst., 85, 1850-1855 (1993).
11. FURR, B.J. and JORDAN, V.C., The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25, 127-205 (1984).
12. GREEN, S., WALTER, P., KUMAR. V., KRUST. V., BORNERT. J.M., ARGOS, P. and CHAMBON, P., Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature (Lond.), 320, 134-139 (1986).
13. HORWITZ, K.B. and MCGUIRE, W.L., Nuclear mechanism of estrogen action. Effect of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J. biol. Chem., 253, 8185-8191 (1978).
14. HOWELL, A., DEFRIEND, D., ROBERTSON, J., BLAMEY, R. and WALTON, P., Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345, 29-30 (1995).
15. KLEDZIK, G.S., CUSAN, L., AUCLAIR, C., KELLY, P.A. and LABRIE, F., Inhibitory effect of luteinizing hormone (LH)-releasing hormone agonist on rat ovarian LH and follicle-stimulating hormone receptor levels during pregnancy. Fertil. Steril., 29, 560-567 (1978).
16. KRAMER, C.Y., Extension of multiple range tests to group means with unique numbers of replications. Biometrics, 12, 307-310 (1956).
17. LABRIE, C., MARTEL, C., DUFOUR, J.M., LÉVESQUE, C., MÉRAND, Y. and LABRIE, F., Novel compounds inhibit estrogen formation and action. Cancer Res., 52, 610-615 (1992).
18. LABRIE, F. and 13 OTHERS. The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. In: V. Hansson, F.O. Levy and K. Taskén (eds.), Signal transduction in testicular cells. Ernst Schering Research Foundation Workshop (Suppl. 2), pp. 185-218, Springer-Verlag, Berlin (1996).
19. LÉVESQUE, C., MÉRAND, Y., DUFOUR, J.M., LABRIE, C. and LABRIE, F., Synthesis and biological activity of new halo-steroidal antiestrogens. J. med. Chem., 34, 1624-1630 (1991).
20. LUU-THE, V., ZHANG, Y., POIRIER, D. and LABRIE, F., Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. J. Steroid biochem. Molec. Biol., 55, 581-587 (1995).
21. MOURIDSEN, H., PALSHOF, T., PATTERSON, J. and BATTERSBY, L., Tamoxifen in advanced breast cancer. Cancer Treat. Rev., 5, 131-141 (1978).
22. PARKER, S.L., TONG, T., BOLDEN, S. and WINGO, P.A., Cancer statistics 1997. CA Cancer J. Clin., 47, 5-27 (1997).
23. 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res., 46, 4933-4937 (1986).
24. POULIN, R., MÉRAND, Y., POIRIER, D., LÉVESQUE, C., DUFOUR, J.M. and LABRIE, F., Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen and ICI164384, a new steroidal antiestrogen. in ZR-75-1 human breast cancer cells. Breast Cancer Res. Treat., 14, 65-76 (1989).
25. SIMARD, J., DAUVOIS, S., HAAGENSEN, D.E., LÉVESQUE, C., MÉRAND, Y. and LABRIE, F., Regulation of progesterone-binding breast cyst protein GC-DFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology, 126, 3223-3231 (1990).
26. WAKELING, A.E., The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat., 25, 1-9 (1993).
27. WAKELING, A.E. and BOWLER, J., Biology and mode of action of pure antiestrogens. J. Steroid Biochem., 30, 141-147 (1988).
28. WAKELING, A.E., DUKES, M. and BOWLER, J., A potent specific pure antiestrogen with clinical potential. Cancer Res., 51, 3867-3873 (1991).